ExSight Ventures Invests in RevOpsis Therapeutics to Advance Wet AMD and DED Treatment Candidate
ExSight Ventures has announced a strategic investment in RevOpsis Therapeutics, a biotechnology company focused on developing a new class of multispecific antibody-based treatments for serious ophthalmic conditions. The initial focus of this partnership is the advancement of therapeutic candidates targeting wet age-related macular degeneration (AMD) and diabetic eye disease.
RevOpsis Therapeutics is developing a novel platform of multispecific antibody-based therapies to address major gaps in the treatment of vision-threatening eye diseases. The company’s initial pipeline efforts are centered on innovative solutions for wet AMD and diabetic eye disease, both of which remain areas of high unmet clinical need.
Strategic Investment by ExSight Ventures
The investment by ExSight Ventures reinforces confidence in the scientific direction and leadership of RevOpsis. Firas Rahhal, MD, General Partner at ExSight Ventures and a specialist at Retina Vitreous Associates Medical Group in Los Angeles, shared the following:
“We are thrilled to support RevOpsis in its mission to bring breakthrough therapies to patients suffering from vision-threatening conditions. Our investment reflects our strong belief in both the scientific foundation of RevOpsis' platform and the experienced leadership team driving its development.”
Funding to Support Clinical Development Efforts
Ram Bhandari, MD, CEO and Co-founder of RevOpsis Therapeutics, highlighted the strategic value of the partnership:
“ExSight Ventures is a leading investor in the ophthalmology space, and their support is a strong validation of our approach. This partnership will help us advance our pipeline toward clinical development and bring us closer to providing patients with more effective and longer-lasting treatment options. ExSight Ventures has a proven track record of backing companies developing innovative solutions in eye care, and this investment further demonstrates its commitment to supporting the next wave of therapeutic breakthroughs in ophthalmology.”
